<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1586">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04585347</url>
  </required_header>
  <id_info>
    <org_study_id>ALZ-801-104</org_study_id>
    <nct_id>NCT04585347</nct_id>
  </id_info>
  <brief_title>Single Dose Study of ALZ-801 Prototype Tablets</brief_title>
  <official_title>Four-Period, Single-Dose, Sequential Study in Healthy Adults, to Assess Pharmacokinetics of ALZ-801 and Tramiprosate From ALZ-801 Prototype Tablets and Effect of Food on Bioavailability of ALZ-801 and Tramiprosate for Selected Prototype Tablet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alzheon Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alzheon Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1, single-center, open-label, non-randomized, sequential single dose 4-period study in&#xD;
      12 healthy subjects to assess the pharmacokinetics of ALZ-801, tramiprosate and the primary&#xD;
      metabolite of tramiprosate, NRM5074, from prototype drug product formulations of ALZ-801, and&#xD;
      to assess effect of food on the bioavailability of ALZ-801 and tramiprosate of the prototype&#xD;
      tablet formulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label, non-randomized, sequential, single-dose, 4-period study&#xD;
      in 12 healthy adult subjects. Subjects are to receive a single oral dose of ALZ-801 in each&#xD;
      of the 4 study periods (Regimens A, B, C and D) in a non-randomized, sequential manner,&#xD;
      separated by a minimum washout period of 7 days. The washout period is expected to last&#xD;
      approximately 14 days to permit interim decisions to take place and to allow for the&#xD;
      selection of the formulation of the subsequent regimen. Periods of interim analysis will take&#xD;
      place following dosing with prototype formulations Regimens A, B, and C, during which the PK&#xD;
      and safety data are reviewed to determine the dose to be administered in the subsequent&#xD;
      treatment period. Interim decisions aim to identify a prototype ALZ-801 immediate release&#xD;
      tablet formulation that provides a similar tramiprosate AUC and Cmax to that of historical&#xD;
      values after administration of a 100 mg loose-filled tramiprosate capsule in the fasted&#xD;
      state.&#xD;
&#xD;
      Optimization of the required tramiprosate exposure will be made by adjusting the dose of&#xD;
      ALZ-801 in the prototype tablets using a formulation design space with a target dose range,&#xD;
      per tablet, of 171 to 514 mg ALZ-801 (equivalent to 100 mg to 300 mg tramiprosate). Dose&#xD;
      selection will be made after a complete review of all data collected from the previous dose&#xD;
      group. For dose selection to occur, data is required to be available from a minimum of 8&#xD;
      evaluable subjects with complete safety assessments up to 24 h post-dose, and required safety&#xD;
      and PK data (AEs, plasma concentrations of ALZ-801, tramiprosate and NRM5074, and Tmax, Cmax&#xD;
      and AUC estimates for ALZ-801 and tramiprosate).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 16, 2015</start_date>
  <completion_date type="Actual">November 13, 2015</completion_date>
  <primary_completion_date type="Actual">November 13, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Subjects were to receive a single oral dose of ALZ-801 in each of the 4 study periods (Regimens A, B, C and D) in a non-randomized, sequential manner, separated by a minimum washout period of 7 days.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax for ALZ-801, tramiprosate, and NRM5074</measure>
    <time_frame>72 hours after dosing</time_frame>
    <description>Maximum observed concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for ALZ-801, tramiprosate, and NRM5074</measure>
    <time_frame>72 hours after dosing</time_frame>
    <description>Time from dosing at which Cmax was apparent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for ALZ-801, tramiprosate, and NRM5074</measure>
    <time_frame>72 hours after dosing</time_frame>
    <description>Area under the curve from time zero to the last measurable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 for ALZ-801, tramiprosate, and NRM5074</measure>
    <time_frame>72 hours after dosing</time_frame>
    <description>The apparent elimination half-lifee</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frel for ALZ-801 and tramiprosate</measure>
    <time_frame>72 hours after dosing</time_frame>
    <description>Relative bioavailability of mean PK parameters (AUC[0-inf] and Cmax) for fasted compared to fed state for ALZ-801 and tramiprosate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frel (test to literature reference)</measure>
    <time_frame>72 hours after dosing</time_frame>
    <description>Relative bioavailability of mean PK parameters (AUC[0-inf] and Cmax) for tramiprosate from ALZ-801 prototype tablet formulation compared to previous tramiprosate Phase 3 data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>72 hours</time_frame>
    <description>Incidence and nature of adverse events (AEs) and serious adverse events (SAEs). Assessments reported as AEs or SAEs include physical examination, clinical laboratory tests, and 12-lead electrocardiogram (ECG) findings</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALZ-801 171 mg tablet, fasting, once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALZ-801 205 mg tablet, fasting, once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALZ-801 205 mg tablet, after food once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALZ-801 342 mg (administered as 2 x 171 mg tablets of ALZ-801), after food, once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALZ-801 170 mg Fasting</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALZ-801 205 mg Fasting</intervention_name>
    <arm_group_label>Regimen B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALZ-801 205 mg After Food</intervention_name>
    <arm_group_label>Regimen C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALZ-801 342 mg Fasting</intervention_name>
    <arm_group_label>Regimen D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males and females&#xD;
&#xD;
          -  Females must be of non-childbearing potential&#xD;
&#xD;
          -  Body mass index (BMI) of 18.0 to 35.0 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any drug or alcohol abuse in the past 2 years&#xD;
&#xD;
          -  Subjects known to have a creatinine clearance of &lt;60 mL/min&#xD;
&#xD;
          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or&#xD;
             human immunodeficiency virus (HIV) results&#xD;
&#xD;
          -  History of cardiovascular, renal, hepatic, neurological, psychiatric, chronic&#xD;
             respiratory or gastrointestinal disease as judged by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Church, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Quotient Clinical</affiliation>
  </overall_official>
  <link>
    <url>http://link.springer.com/article/10.1007%2Fs40262-017-0608-3</url>
    <description>Clinical Pharmacokinetics and Safety of ALZ-801</description>
  </link>
  <results_reference>
    <citation>Hey JA, Yu JY, Versavel M, Abushakra S, Kocis P, Power A, Kaplan PL, Amedio J, Tolar M. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease. Clin Pharmacokinet. 2018 Mar;57(3):315-333. doi: 10.1007/s40262-017-0608-3.</citation>
    <PMID>29063518</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

